SYNGENE Syngene International Q3 FY25 results (Oct–Dec 2024) and concall
Syngene reported a strong recovery in Q3 FY25 with 11% revenue growth and significant margin expansion, driven by a return to growth in Discovery Services and continued traction in Biologics. While the US biotech funding environment is stabilizing, the recovery is taking 8-12 weeks longer than management initially anticipated, leading to a moderated full-year revenue outlook. The company is successfully converting 'China Plus One' pilot projects into long-term contracts and expects its newly acquired Unit-III facility to be operational by April 2025.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 891 | 944 |
| EBITDA | 245 | 284 |
| Net profit | 106 | 131 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
